Octavio Espinoza net worth and biography

Octavio Espinoza Biography and Net Worth

Mr. Espinoza has been with Ligand since 2016 serving in a variety of finance leadership roles at Ligand, most recently as Senior Vice President, Finance. Prior to joining Ligand, Mr. Espinoza served as Senior Director, Finance for Receptos, a publicly traded drug-discovery company, that was acquired by Celgene (now Bristol-Myers Squibb). Before Receptos, Mr. Espinoza was Senior Director, Accounting for Illumina, a publicly traded life sciences analytics and genetics sequencing tools company, and prior to Illumina, served as Senior Manager, Accounting at Intuit. Mr. Espinoza began his professional career in public accounting at PricewaterhouseCoopers and holds a B.S. in business administration from San Diego State University and a license as a Certified Public Accountant in the State of California.

What is Octavio Espinoza's net worth?: The estimated net worth of Octavio Espinoza is at least $5.27 million as of May 9th, 2025. Mr. Espinoza owns 27,932 shares of Ligand Pharmaceuticals stock worth more than $5,265,182 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Espinoza may own. Additionally, Mr. Espinoza receives a salary of $613,590.00 as CFO at Ligand Pharmaceuticals. Learn More about Octavio Espinoza's net worth.
How old is Octavio Espinoza?: Mr. Espinoza is currently 53 years old. There are 4 older executives and no younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals is Mr. Scott M. Plesha, Chief Executive Officer, who is 59 years old. Learn More on Octavio Espinoza's age.
What is Octavio Espinoza's salary?: As the CFO of Ligand Pharmaceuticals Incorporated, Mr. Espinoza earns $613,590.00 per year. There are 2 executives that earn more than Mr. Espinoza. The highest earning executive at Ligand Pharmaceuticals is Mr. Matthew E. Korenberg, President & COO, who commands a salary of $831,770.00 per year. Learn More on Octavio Espinoza's salary.
How do I contact Octavio Espinoza?: The corporate mailing address for Mr. Espinoza and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on Octavio Espinoza's contact information.
Has Octavio Espinoza been buying or selling shares of Ligand Pharmaceuticals?: Octavio Espinoza has not been actively trading shares of Ligand Pharmaceuticals during the last ninety days. Most recently, on Friday, May 9th, Octavio Espinoza bought 1,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $104.06 per share, with a total value of $156,090.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $2,906,603.92. Learn More on Octavio Espinoza's trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 2 times. They purchased a total of 11,010 shares worth more than $1,156,542.00. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 22,373 shares worth more than $3,264,991.97. The most recent insider tranaction occured on December, 1st when Director John W Kozarich sold 467 shares worth more than $91,457.28. Insiders at Ligand Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 12/1/2025.

Octavio Espinoza Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2025	Buy	1,500	$104.06	$156,090.00	27,932
3/4/2025	Sell	5,000	$115.03	$575,150.00	18,879
12/23/2024	Sell	2,104	$116.37	$244,842.48	20,647
9/20/2024	Sell	1,275	$103.94	$132,523.50	24,610
5/17/2024	Sell	5,156	$86.66	$446,818.96	23,379
5/15/2024	Sell	5,873	$86.01	$505,136.73	23,882
2/28/2024	Sell	140	$88.46	$12,384.40	29,755
11/9/2022	Sell	1,696	$75.64	$128,285.44	8,857

Octavio Espinoza Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $188.50

$187.87

$194.90

50 Day Range

MA: $191.39

$169.72

$209.29

2 Week Range

Now: $188.50

$93.58

$212.49

Volume

194,343 shs

Average Volume

226,796 shs

Market Capitalization

$3.71 billion

P/E Ratio

91.06

Dividend Yield

N/A

Beta

0.99

Octavio Espinoza Biography and Net Worth

What is Octavio Espinoza's net worth?

How old is Octavio Espinoza?

What is Octavio Espinoza's salary?

How do I contact Octavio Espinoza?

Has Octavio Espinoza been buying or selling shares of Ligand Pharmaceuticals?

Who are Ligand Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Ligand Pharmaceuticals?